jRCT2031240625尚未招募不适用
A Phase II, single-arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50
- 主要终点
- treatment emergent AEs
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patient is ongoing on brigimadlin treatment or qualifies for crossover to brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the (parent trial)).
- •Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- •Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
- •Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
- •Adequate organ function.
- •All toxicities related to previous anti-cancer therapies have resolved Common Terminology Criteria for Adverse Events (CTCAE) Grade <1 prior to trial treatment administration (except for alopecia and amenorrhea/menstrual disorders which can be any grade and peripheral neuropathy which must be CTCAE Grade <2).
- •Cohort 1 only:
- •Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial.
- •Cohort 2 only:
- •Patient is eligible to receive crossover treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients must transition directly from the parent trial to this trial, with no further anti-cancer therapies except those that are allowed by the clinical trial protocol of the parent trial.
- •Further inclusion criteria apply.
排除标准
- •Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin.
- •Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- •Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment.
- •Cohort 1 only:
- •Patient has disease progression or unacceptable toxicity on brigimadlin at the time of transition into this trial.
- •Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial.
- •Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed between the investigator and the sponsor.
- •Further exclusion criteria apply.
结局指标
主要结局
treatment emergent AEs
时间窗: during the entire treatment period
The occurrence of treatment emergent AEs according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Clinical trial to investigate the effect of long-term intake of tomato juice on atherosclelosisMetabolic symdromeJPRN-UMIN000001173Tokushima University Hospital40
尚未招募
1 期
effect of devdaruvadi churna,shunthyadi kwatha and saindhwadi tail matra basti in AMAVATA (RHEUMATOID ARTHRITIS)CTRI/2019/02/017640Rishikul Campus
已完成
不适用
Clinical trial on efficacy and safety of long-term Rebamipide therapy for successful eradication of Helicobacter pylori.Patients who successful eradication therapy of Helicobacter pylori.JPRN-UMIN000002369Department of Internal Medicine, division of Gastroenterology Kawasaki Medical School250
尚未招募
4 期
A longitudinal randomized clinical trial of participants satisfaction of two mandibular implant-retained overdentures, with ball, bar or locator attachment, in patients with severe resorption of the mandible.dental implantsmandibular implant-retained overdentureprosthesis1002445010005944NL-OMON35749Academisch Medisch Centrum660
尚未招募
4 期
A longitudinal randomized clinical trial of participants satisfaction of three or four mandibular implant-retained overdentures, with bar attachment, in patients with severe resorption of the mandible.dental implantsmandibular implant-retained overdentureprosthesis1002445010005944NL-OMON36109Academisch Medisch Centrum420